Merck (MRK) reported Q4 FY 2020 earnings of $1.32 per share (versus $1.16 per share in Q4 FY 2019), missing analysts’ consensus estimate of $1.39 per share.
The company’s quarterly revenues amounted to $12.514 bln (+5.4% y/y), missing analysts’ consensus estimate of $12.650 bln.
The company also issued upside guidance for FY 2021, projecting EPS of $6-48-6.68 versus analysts’ consensus estimate of $6.19 and revenues of $51.8-53.8 bln versus analysts’ consensus estimate of $51.58 bln.
MRK rose to $77.40 (+0.10%) in pre-market trading.